A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Drug Discovery and Structural Biology (DDSB) Core Bookmark and Share

Drug Discovery and Structural Biology (DDSB) Core

A primary goal of City of Hope's Comprehensive Cancer Center and its research programs is to develop new, more effective and less toxic therapies for the treatment of cancer. The Drug Discovery and Structural Biology (DDSB) Core was established to provide the necessary technical and scientific resource to facilitate drug discovery efforts consistent with the cancer center’s translational research goals. An important focus of the DDSB is on cancer drug discovery in the area of molecular-targeted therapeutics, as well as chemical biology probes. The core was established with these goals in mind and therefore is highly diverse in its services, yet highly convergent in its efforts.  The core comprises four major service components: high throughput screening, biopolymer synthesis, small molecule synthesis and X-ray crystallography. These disciplines work together in a complementary and cohesive manner to provide a full array of early-phase drug discovery services and chemical probes for biological systems. 
 
For example, the high throughput screening component of the DDSB provides unique opportunities for discovering small-molecule inhibitors of targeted proteins. Next, lead compounds can be elaborated through medicinal chemistry and structure activity relationship studies.  Once a good lead compound is developed, X-ray crystallographic analysis of the drug-protein complex begins. This is an essential component of any drug development process, since a detailed structural analysis is critical to understanding the drug-protein interaction and facilitates the optimization of ligand binding by molecular design. The general capabilities of the DDSB are significant and include the design and synthesis of highly specialized biopolymers, including siRNA-aptamers, DNA-peptide hybrid derivatives and peptides >100 amino acids in length.  In addition, the core maintains expertise in synthetic organic chemistry and is capable of complex molecule synthesis as well as the synthesis of small-molecule agonists and antagonists, imaging agents, affinity ligands, nanoparticles and focused combinatorial libraries. These compounds are used for mechanistic studies in chemical biology, generation of lead compounds for drug discovery, drug optimization for preclinical evaluation and, ultimately, development of new-targeted cancer therapeutics. 
 
The DDSB is capable of synthesizing all structural classes from small to large organic molecules including air- and light-sensitive materials. The synthetic component of the DDSB works closely with the new Chemical GMP Synthesis Facilities in developing good manufacturing practice synthesis processes for investigational new drug submissions. The other significant aspect of the DDSB lies in the structural characterization of drug-protein complexes by X-ray crystallography and other biophysical techniques such as surface plasmon resonance, isothermal titration calorimetry, and analytical ultracentrifugation. This unique transdisciplinary core enables development of new molecularly-targeted compounds for chemical biology studies and cancer therapies to enhance our translational research mission of the City of Hope Comprehensive Cancer Center. The goal of developing targeted molecular cancer therapeutics within various research programs of the cancer center is greatly facilitated through the newly-expanded, integrated DDSB facility.
 
Any subcomponent of the DDSB can be utilized on a stand-alone basis for a specific application.  Please contact the co-directors or managers at the links below for more information on usage, pricing and availability.
 
David Horne, Ph.D.
Co-director
626-256-4673, ext. 67310
dhorne@coh.org
 
John C. Williams, Ph.D.
Co-director
626-256-HOPE (4673), ext. 60227
jwilliams@coh.org

Drug Discovery and Structural Biology (DDSB) Core

Drug Discovery and Structural Biology (DDSB) Core

A primary goal of City of Hope's Comprehensive Cancer Center and its research programs is to develop new, more effective and less toxic therapies for the treatment of cancer. The Drug Discovery and Structural Biology (DDSB) Core was established to provide the necessary technical and scientific resource to facilitate drug discovery efforts consistent with the cancer center’s translational research goals. An important focus of the DDSB is on cancer drug discovery in the area of molecular-targeted therapeutics, as well as chemical biology probes. The core was established with these goals in mind and therefore is highly diverse in its services, yet highly convergent in its efforts.  The core comprises four major service components: high throughput screening, biopolymer synthesis, small molecule synthesis and X-ray crystallography. These disciplines work together in a complementary and cohesive manner to provide a full array of early-phase drug discovery services and chemical probes for biological systems. 
 
For example, the high throughput screening component of the DDSB provides unique opportunities for discovering small-molecule inhibitors of targeted proteins. Next, lead compounds can be elaborated through medicinal chemistry and structure activity relationship studies.  Once a good lead compound is developed, X-ray crystallographic analysis of the drug-protein complex begins. This is an essential component of any drug development process, since a detailed structural analysis is critical to understanding the drug-protein interaction and facilitates the optimization of ligand binding by molecular design. The general capabilities of the DDSB are significant and include the design and synthesis of highly specialized biopolymers, including siRNA-aptamers, DNA-peptide hybrid derivatives and peptides >100 amino acids in length.  In addition, the core maintains expertise in synthetic organic chemistry and is capable of complex molecule synthesis as well as the synthesis of small-molecule agonists and antagonists, imaging agents, affinity ligands, nanoparticles and focused combinatorial libraries. These compounds are used for mechanistic studies in chemical biology, generation of lead compounds for drug discovery, drug optimization for preclinical evaluation and, ultimately, development of new-targeted cancer therapeutics. 
 
The DDSB is capable of synthesizing all structural classes from small to large organic molecules including air- and light-sensitive materials. The synthetic component of the DDSB works closely with the new Chemical GMP Synthesis Facilities in developing good manufacturing practice synthesis processes for investigational new drug submissions. The other significant aspect of the DDSB lies in the structural characterization of drug-protein complexes by X-ray crystallography and other biophysical techniques such as surface plasmon resonance, isothermal titration calorimetry, and analytical ultracentrifugation. This unique transdisciplinary core enables development of new molecularly-targeted compounds for chemical biology studies and cancer therapies to enhance our translational research mission of the City of Hope Comprehensive Cancer Center. The goal of developing targeted molecular cancer therapeutics within various research programs of the cancer center is greatly facilitated through the newly-expanded, integrated DDSB facility.
 
Any subcomponent of the DDSB can be utilized on a stand-alone basis for a specific application.  Please contact the co-directors or managers at the links below for more information on usage, pricing and availability.
 
David Horne, Ph.D.
Co-director
626-256-4673, ext. 67310
dhorne@coh.org
 
John C. Williams, Ph.D.
Co-director
626-256-HOPE (4673), ext. 60227
jwilliams@coh.org
Research Shared Services

City of Hope embodies the spirit of scientific collaboration by sharing services and core facilities with colleagues here and around the world.
 

Recognized nationwide for its innovative biomedical research, City of Hope's Beckman Research Institute is home to some of the most tenacious and creative minds in science.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 
Media Inquiries/Social Media

For media inquiries contact:

Dominique Grignetti
800-888-5323
dgrignetti@coh.org

 

For sponsorships inquiries please contact:

Stefanie Sprester
213-241-7160
ssprester@coh.org

Christine Nassr
213-241-7112
cnassr@coh.org

 
CONNECT WITH US
Facebook  Twitter  YouTube  Blog
 
NEWS & UPDATES
  • Beyond the pink ribbons, special product fundraisers, and the pastel sea of color that marks October, Breast Cancer Awareness Month offers a reason to celebrate and to reflect. More than 2.8 million breast cancer survivors live in the U.S. They are survivors of the second most-common cancer in women, behind ski...
  • Gliomas, a type of tumor that grows in the brain, are very difficult to treat successfully due to their complex nature. That might not always be the case. First some background: The most aggressive and common type of primary brain tumor in adults is glioblastoma. Although the brain tumor mass can often be remov...
  • Cutaneous T cell lymphomas are types of non-Hodgkin lymphoma that arise when infection-fighting white blood cells in the lymphatic system – called lymphocytes – become malignant and affect the skin. The result is rashes and, sometimes, tumors, which can be mistaken for other dermatological conditions. In a smal...
  • Weighing your breast cancer risk? One study suggests a measure to consider is skirt size. A British study suggests that for each increase in skirt size every 10 years after age 25, the five-year risk of developing breast cancer postmenopause increases from one in 61 to one in 51 – a 77 percent increase in risk....
  • Runners prize medals for 5Ks and marathons. Becky Stokes has a medal she cherishes from a very different kind of race: the marathon of treatments necessary to beat her aggressive triple-negative breast cancer. Just a week ago, she completed her last radiation treatment, and danced in the hospital with the staff...
  • Rob Darakjian was diagnosed with acute lymphoblastic leukemia at just 19 years old. He began chemotherapy and was in and out of the hospital for four months. After his fourth round of treatment, he received a bone marrow transplantation from an anonymous donor. Today, he’s cancer free. Darakjian’s s...
  • The environment plays a role in causing cancer – this much we know. But scientists are still trying to understand what that role is, what environmental factors are in play and how precisely those factors are linked to cancer. Now City of Hope researchers have unlocked a clue as to how one carcinogen triggers ca...
  • Jonathan Yamzon, M.D., assistant clinical professor of surgery in the Division of Urology and Urologic Oncology, explains his approach to what’s known as “active surveillance” of men with prostate cancer. Patients need to be educated about their treatment options, he writes. Active surveillanc...
  • For most prostate cancer patients, surgery or radiation therapy is the initial and primary treatment against the disease. But some patients can benefit from chemotherapy and hormone therapy too, especially if there are signs of a relapse or if the cancer has spread beyond the prostate gland. Here, Cy Stein, M.D...
  • Cancer research has yielded scientific breakthroughs that offer patients more options, more hope for survival and a higher quality of life than ever before. The 14.5 million cancer patients living in the United States are living proof that cancer research saves lives. Now, in addition to the clinic, hospital an...
  • Advances in cancer treatment, built on discoveries made in the laboratory then brought to the bedside, have phenomenally changed the reality of living with a cancer diagnosis. More than any other time in history, people diagnosed with cancer are more likely to survive and to enjoy a high quality of life. Howeve...
  • While health care reform has led to an increase in the number of people signing up for health insurance, many people remain uninsured or are not taking full advantage of the health benefits they now have. Still others are finding that, although their premiums are affordable, they aren’t able to see the do...
  • Kidney cancer rates and thyroid cancer rates in adults have continued to rise year after year. Now a new study has found that incidence rates for these cancers are also increasing in children — particularly in African-American children. The study, published online this month in Pediatrics, examined childhood ca...
  • Thyroid cancer has become one of the fastest-growing cancers in the United States for both men and women. The chance of being diagnosed with the cancer has nearly doubled since 1990. This year an estimated 63,000 people will be diagnosed with thyroid cancer in the United States and nearly 1,900 people will die ...
  • Older teenagers and young adults traditionally face worse outcomes than younger children when diagnosed with brain cancer and other central nervous system tumors. A first-of-its-kind study shows why. A team of researchers from the departments of Population Sciences and Pathology at City of Hope recently examine...